11 / 11
Page 42
Notes:
Journal of Neurology and Neurorehabilitation Research | Volume 3
allied
academies
November 26-27, 2018 | Dubai, UAE
Spine and Spine Disorders
Addiction Research and Therapy
3rd International Conference on
International Conference on
Joint Event
&
L
umbar degenerative disc disease (DDD ) poses an ongoing
challenge as far as treatment options and alternatives,
especially when considering younger patients. Over 80% of
the adult population presents with one or more episodes of
ongoing-progressive low-back pain (LBP ). The primary cause
is associated with degeneration of the intervertebral disc and
which is triggered by a decrease of the nucleus pulposus cell
population, as evidenced in histological studies. Definitely, in the
presence of a "black disc" without profusion and neurological
compromise, microsurgery or even fusion surgery should not be
contemplated. Numerous percutaneous techniques have been
propagated as proper way to treat this condition throughout the
literature in the past years. They have been primarily focused on
the treatment of the pain generated by the involved disc and
the subsequent segmental insufficiency, without addressing
the degeneration of the disc and for this have had limited
success and remain as pain management tools. Some significant
trials in the past ( i.e. Chondrocyte transplantation trial ) and
the increasing recent research and achievements with more
biological strategies as far as tissue regeneration , havemotivated
the development of a new treatment concept initially applicable
to the lumbar spine which will be presented and discussed.
Advancements have led to a significant improvement in the
understanding of the cell environment and tissue transplantation
at amolecular, cellularand immunobiological level.Adiposetissue
has already become a central source of clinical and researchwork
involving adipose tissue derived progenitor cells. Endothelial and
mesenchymal stem cells derived from adipose tissue are being
considered and used in an array of clinical conditions and seem
to have clear therapeutic benefits for many disease conditions
including those affecting bone, cartilage and muscle. The use
of an accessible source with abundant cells which have a high
potential for regeneration clearly is superior in comparison to
the chondrocyte option for the lumbar disc. Mesenchymal cells
have a high self renewal capacity and a potential for multi lineage
differentiation. For this, adipose tissue derived MSCs (ADMSCs)
are optimal candidates for tissue regeneration and can be
obtained from the patient in a one step procedure-treatment.
Speaker Biography
Walter Bini has completed his diploma at Westminster School, Simsbury Conn,
USA and post-graduate degree at Universidad de Zaragoza, Facultad de Medicina,
Zaragoza-Spain. In 2014, he was the Middle East Chairman of ISLASS. He was
head of Neurosurgery at Sheikh Khalifa General Hospital, UAQ-UAE from 2014-
2016. Currently, he is Consultant Neurosurgeon in Orthopedic Department,
spine section of Lanzo Hospital COF, Lanzo d’Intelvi in Italy and also visiting
consultant Neurosurgeon in Orthopedic Department at Healthpoint Hospital,
UAE. Currently he is Neurosurgeon at Waldkrankenhaus Bad Duben, Germany.
e:
binidr4@gmail.comWalter Bini
Waldkrankenhaus Bad Duben, Germany
Adipose derived mesenchymal stem cells in the treatment of DDD. Protocol and personal
experience